P/E at 37.2 vs Industry's 35.74: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflects Confidence Amid Sector Dynamics

The current P/E of 37.20 for Sun Pharmaceutical Industries Ltd sits slightly above the Pharmaceuticals & Biotechnology industry average of 35.74. This premium, though not extreme, suggests investors are willing to pay more for the company’s earnings relative to its peers. Such a valuation can imply expectations of superior earnings growth or a perception of stronger fundamentals. However, the premium also invites scrutiny on whether the stock’s price adequately reflects risks or if it is vulnerable to a correction should earnings disappoint. Sun Pharma’s market capitalisation of ₹4,65,686.92 crores confirms its large-cap status, which often commands a valuation premium due to perceived stability and liquidity.

Performance Across Timeframes: Divergent Momentum Signals

Examining returns across multiple periods reveals a compelling divergence. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 14.76% gain, significantly outperforming the Sensex’s 5.10% loss. This outperformance extends to the three-month horizon, where the stock surged 16.36% while the Sensex declined 1.19%. The one-month return of 5.65% also surpasses the Sensex’s 1.02% gain, indicating sustained positive momentum in recent months.

Shorter-term performance remains positive as well, with a one-week gain of 0.88% versus a flat Sensex and a one-day advance of 0.40% compared to the Sensex’s 0.72% decline. Year-to-date, the stock has appreciated 12.86%, contrasting with the Sensex’s 8.96% fall. This consistent outperformance across timeframes suggests resilience and investor preference within the sector. Sun Pharma’s ability to maintain gains amid broader market weakness raises the question should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Moving Average Configuration: Bullish Across All Key Periods

The technical picture for Sun Pharmaceutical Industries Ltd is notably constructive. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong upward trend across both short and long-term horizons. This alignment of moving averages typically indicates sustained buying interest and a positive momentum backdrop. The recent gain after two consecutive days of decline further supports the notion of a resilient recovery rather than a fleeting bounce. However, the stock’s intraday volatility of 140.02% today highlights that despite the upward trend, price swings remain significant, which may warrant caution for risk-averse investors.

Trading close to its 52-week high—just 0.64% away from ₹1962.5—Sun Pharma appears to be consolidating near peak levels. This proximity to the high raises the analytical question is this a genuine breakout or a potential resistance zone that could cap further gains?

Sector Performance Context: Pharmaceuticals & Biotechnology Holding Steady

The Pharmaceuticals & Biotechnology sector has experienced mixed results recently, with a blend of positive, flat, and negative performances among constituent stocks. Sun Pharmaceutical Industries Ltd stands out as a relative outperformer within this environment, consistently delivering gains while some peers have struggled. This sector resilience is underpinned by ongoing demand for pharmaceutical products and innovation in biotechnology, though regulatory and pricing pressures remain persistent headwinds. The stock’s premium valuation relative to the sector P/E reflects its leadership position and perceived stability amid these challenges.

Rating Reassessment: Previously Rated Hold, Now Updated

On 8 June 2026, Sun Pharmaceutical Industries Ltd had its rating updated from a previous Hold, according to MarketsMOJO. While the current rating is not disclosed, the reassessment coincides with the stock’s strong performance and technical strength. The Mojo Score of 74.0 supports a positive view, reflecting favourable fundamentals and momentum. This rating update invites investors to consider what is the current rating? and how it aligns with the stock’s valuation and price action.

Long-Term Performance: Strong Gains with Some Relative Lag

Over a three-year period, Sun Pharmaceutical Industries Ltd has delivered a 76.96% return, significantly outperforming the Sensex’s 14.82% gain. The five-year performance is even more impressive at 186.75%, compared to the Sensex’s 48.64%. However, the ten-year return of 143.53% trails the Sensex’s 177.93%, indicating that while the stock has been a strong performer in recent years, it has lagged the broader market over the longer term. This divergence may reflect sector-specific cycles or company-specific challenges in the past decade. The strong recent momentum, however, suggests a shift in trajectory that is being recognised by the market.

Intraday and Volatility Insights: High Volatility Amid Positive Momentum

Today, Sun Pharmaceutical Industries Ltd outperformed its sector by 0.86% and gained 0.40% despite the Sensex falling 0.72%. The stock’s intraday volatility of 140.02% is unusually high, signalling significant price swings within the session. Such volatility can be a double-edged sword, offering trading opportunities but also increasing risk. The recent two-day decline followed by a gain today may indicate a short-term consolidation phase within a broader uptrend. This volatility profile should be considered alongside the stock’s technical strength and valuation premium when analysing its near-term prospects.

Conclusion: Data Reflects a Stock in Strong Form but Valuation Requires Scrutiny

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock with solid recent performance, a modest valuation premium, and a bullish technical setup. Its consistent outperformance across multiple timeframes versus the Sensex and sector peers underscores its resilience. Trading above all major moving averages and near its 52-week high further confirms positive momentum. However, the premium P/E ratio and elevated intraday volatility suggest that investors should carefully weigh valuation against risk. The recent rating reassessment from Hold invites the question what is the current rating? and how it aligns with the evolving data landscape.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →